/DCTH
DCTH Stock - Delcath Systems, Inc.
Healthcare|Medical - DevicesNASDAQ
$10.06+1.31%
+$0.13 (+1.31%) • Dec 19
74
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.34
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+148.5%upside
Target: $25.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DCTH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$9.96 – $10.16
TARGET (TP)$25.00
STOP LOSS$9.26
RISK/REWARD1:18.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.41
52W High$18.23
52W Low$8.12
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $37.20M | $2.06M | $2.72M | $3.56M | $1.65M |
| Gross Profit | $31.02M | $1.43M | $2.03M | $2.88M | $1.01M |
| Gross Margin | 83.4% | 69.2% | 74.8% | 81.1% | 61.1% |
| Operating Income | $-12,410,000 | $-38,182,000 | $-33,853,000 | $-24,531,000 | $-21,303,000 |
| Net Income | $-26,386,000 | $-47,678,000 | $-36,508,000 | $-25,649,000 | $-24,156,000 |
| Net Margin | -70.9% | -2308.9% | -1342.7% | -721.5% | -1467.6% |
| EPS | $-0.93 | $-2.94 | $-4.12 | $-3.59 | $-8.35 |
Company Overview
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$20
Average Target
↑ 98.8% Upside
Now
$17
Low
$20
Average
$25
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 28th 2024 | Craig Hallum | Initiation | Buy | $18 |
| May 14th 2024 | Stephens | Initiation | Overweight | $25 |
| July 26th 2022 | Canaccord Genuity | Resumed | Buy | $17 |
Earnings History & Surprises
DCTHBeat Rate
44%
Last 18 quarters
Avg Surprise
+12.7%
EPS vs Estimate
Beats / Misses
8/8
2 met exactly
Latest EPS
$0.02
Q4 2025
EPS Surprise History
Q1 24
+28.4%
$-0.48vs$-0.67
Q2 24
0.0%
$-0.43vs$-0.43
Q3 24
-41.2%
$-0.48vs$-0.34
Q4 24
+76.9%
$-0.03vs$-0.13
Q1 25
+150.0%
$0.05vs$-0.10
Q2 25
-70.0%
$0.03vs$0.10
Q3 25
+169.2%
$0.07vs$0.03
Q4 25
0.0%
$0.02vs$0.02
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | $-0.06 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.02 | $0.02 | 0.0% | = MET |
Q3 2025 | Aug 6, 2025 | $0.03 | $0.07 | +169.2% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $0.10 | $0.03 | -70.0% | ✗ MISS |
Q1 2025 | Mar 6, 2025 | $-0.10 | $0.05 | +150.0% | ✓ BEAT |
Q4 2024 | Nov 8, 2024 | $-0.13 | $-0.03 | +76.9% | ✓ BEAT |
Q3 2024 | Aug 5, 2024 | $-0.34 | $-0.48 | -41.2% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.43 | $-0.43 | 0.0% | = MET |
Q1 2024 | Mar 26, 2024 | $-0.67 | $-0.48 | +28.4% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.51 | $-0.61 | -19.6% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-0.67 | $-0.58 | +13.4% | ✓ BEAT |
Q2 2023 | May 22, 2023 | $-0.57 | $-0.77 | -35.1% | ✗ MISS |
Q1 2023 | Mar 27, 2023 | $-0.68 | $-0.86 | -26.5% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-1.05 | $-0.92 | +12.4% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.88 | $-1.18 | -34.1% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.84 | $-1.00 | -19.0% | ✗ MISS |
Q1 2022 | Mar 25, 2022 | $-0.93 | $-0.69 | +25.8% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $-0.91 | $-0.94 | -3.3% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-0.98 | $-0.96 | +2.0% | ✓ BEAT |
Latest News
Delcath Systems 10-Year Data From Retrospective Study On Patients With Liver-Dominant Metastatic Uveal Melanoma Shows Safety, Efficacy Of CHEMOSAT
📈 PositiveBenzinga•Dec 3, 2025, 09:06 PM
Delcath Systems Announces $25M Buyback Plan
📈 PositiveBenzinga•Nov 20, 2025, 09:02 PM
Delcath Systems Announces Retrospective Study From The University Of Tubingen, Analyzing Long-Term Survivors With Liver Metastases From Uveal Melanoma
📈 PositiveBenzinga•Nov 13, 2025, 01:39 PM
Stephens & Co. Maintains Overweight on Delcath Systems, Lowers Price Target to $18
➖ NeutralBenzinga•Nov 5, 2025, 02:58 PM
Delcath Systems shares are trading lower after the company reported mixed Q3 financial results.
📉 NegativeBenzinga•Nov 4, 2025, 05:24 PM
BTIG Reiterates Buy on Delcath Systems, Maintains $23 Price Target
📈 PositiveBenzinga•Nov 4, 2025, 05:10 PM
Delcath Systems Projects $83–$85 Million Revenue In 2025 With 150% Volume Growth, 85–87% Margins, And Positive EBITDA Each Quarter
📈 PositiveBenzinga•Nov 4, 2025, 01:08 PM
Delcath Systems Q3 EPS $0.02 Beats $0.01 Estimate, Sales $20.563M Miss $20.907M Estimate
📈 PositiveBenzinga•Nov 4, 2025, 01:01 PM
Canaccord Genuity Maintains Buy on Delcath Systems, Maintains $21 Price Target
📈 PositiveBenzinga•Oct 21, 2025, 04:29 PM•Also:
HC Wainwright & Co. Maintains Buy on Delcath Systems, Lowers Price Target to $30
📈 PositiveBenzinga•Oct 20, 2025, 03:49 PM
Reported Saturday, Delcath Systems' Phase 2 CHOPIN Study Achieves Primary Endpoint, With PHP Plus Immunotherapy Extending Median PFS To 12.8 Months Versus 8.3 Months
📈 PositiveBenzinga•Oct 20, 2025, 07:53 AM
Reported Saturday, Delcath Systems Posts $20.5M Q3 Revenue, $0.8M Net Income And 87% Gross Margin; Sees 2025 Revenue Outlook Of $83M–$85M With 150% Treatment Volume Growth Forecast
📈 PositiveBenzinga•Oct 20, 2025, 07:52 AM
Delcath Systems Announces The Acceptance Of An Oral Presentation On Results From The Investigator-Initiated CHOPIN Randomized Phase 2 Trial At The 2025 European Society For Medical Oncology Annual Congress
📈 PositiveBenzinga•Sep 22, 2025, 08:03 PM
Delcath Systems Doses First Patient In Phase 2 Clinical Trial Of HEPZATO For Liver-Dominant Metastatic Colorectal Cancer
📈 PositiveBenzinga•Aug 19, 2025, 12:38 PM
Frequently Asked Questions about DCTH
What is DCTH's current stock price?
Delcath Systems, Inc. (DCTH) is currently trading at $10.06 per share. The stock has moved +1.31% today.
What is the analyst price target for DCTH?
The average analyst price target for DCTH is $25.00, based on 1 analyst.
What sector is Delcath Systems, Inc. in?
Delcath Systems, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is DCTH's market cap?
Delcath Systems, Inc. has a market capitalization of $0.35 billion, making it a small-cap company.
Does DCTH pay dividends?
No, Delcath Systems, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAGL
Agilon Health, Inc.
$0.73
Mkt Cap: $0.3B
BWAY
BrainsWay Ltd.
$17.11
Mkt Cap: $0.3B
CERS
Cerus Corporation
$2.09
Mkt Cap: $0.4B
MASS
908 Devices Inc.
$5.84
Mkt Cap: $0.2B
NAKA
Kindly MD, Inc.
$0.39
Mkt Cap: $0.1B
NPCE
NeuroPace, Inc.
$16.59
Mkt Cap: $0.6B
RXST
RxSight, Inc.
$12.03
Mkt Cap: $0.5B
SENS
Senseonics Holdings, Inc.
$6.15
Mkt Cap: $0.3B
SMLR
Semler Scientific, Inc.
$17.93
Mkt Cap: $0.3B
TCMD
Tactile Systems Technology, Inc.
$28.92
Mkt Cap: $0.6B
Explore stocks similar to DCTH for comparison